

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Sanai Health Industry Group Company Limited

三愛健康產業集團有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 1889)

RESULTS OF INTERNAL CONTROL REVIEW

Reference is made to the regulatory news release published by The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”) on 3 September 2020 (the “**News Release**”) and the announcement dated 17 September 2020, 22 December 2020, 10 February 2021 and 11 May 2021 of Sanai Health Industry Group Company Limited (the “**Company**”, and together with its subsidiaries, the “**Group**”) in relation to the appointment of internal control adviser, results of internal control review and completion of director training (the “**Announcements**”).

INTERNAL CONTROL REVIEW REPORT

As part of the remedial measures required by the Stock Exchange set out in the News Release to improve the internal control system, the Company has appointed Zhonghui Anda Risk Services Limited as the independent professional adviser of the Company on 17 September 2020 (the “**Internal Control Adviser**”) to conduct a thorough review of and make recommendations to improve the Company’s internal control system (the “**Internal Control Review**”). The purpose of the Internal Control Review is to review and improve the internal control system designed and implemented by the Company’s management to ensure compliance with the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”).

On 30 July 2021, the Company provided the Stock Exchange with a final review report (the “**Review Report**”) of the Internal Control Review by the Internal Control Adviser. According to the Review Report, the Company has implemented all the recommendations in the Review Report and all the control deficiencies identified in the Review Report have been rectified.

The Board of the Directors of the Company hereby confirmed that the Company has fully complied with each of the directions in paragraphs (3) to (5) stated in the News Release.

CONTINUED SUSPENSION OF TRADING

At the request of the Company, trading in the shares of the Company on the Stock Exchange has been suspended with effect from 9:00 a.m. on Friday, 24 January 2020 and will remain suspended until the Company fulfills the Resumption Conditions.

Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.

By order of the Board
Sanai Health Industry Group Company Limited
Chen Chengqing
Chairman

Hong Kong, 11 August 2021

As at the date of this announcement, the Board comprises five executive directors, namely, Mr. Chen Chengqing (Chairman), Mr. Gao Borui, Mr. Yuan Chaoyang, Professor Zhang Rongqing and Mr. She Hao, one non-executive director, namely, Mr. Xiu Yuan and three independent non-executive directors, namely, Professor Zhu Yi Zhun, Mr. Khor Khie Liem, Alex and Mr. Zhang Ruigen.